Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: Studies using HLA transgenic mice

Journal of Autoimmunity

Volumn 37, Issue 2, 2011, Pages 122-128

  Luckey, David ^a   Bastakoty, Dikshya ^a   Mangalam, Ashutosh K ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti myelin antibody; Complement; Cytokine; EAE MS; HLA transgenic mice

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DQ8 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 23; PROTEOLIPID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE RESISTANCE; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TH17 CELL;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE-ENVIRONMENT INTERACTION; GENES, MHC CLASS II; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC;

EID: 80052674692     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.05.001     Document Type: Article

References (71)

1. Alvarado-de la Barrera C., Zuniga-Ramos J., Ruiz-Morales J.A., Estanol B., Granados J., Llorente L. HLA class II genotypes in Mexican Mestizos with familial and nonfamilial multiple sclerosis. Neurology 2000, 55:1897-1900.
2. Barcellos L.F., Oksenberg J.R., Begovich A.B., Martin E.R., Schmidt S., Vittinghoff E., et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. American Journal of Human Genetics 2003, 72:710-716.
3. DeLuca G.C., Ramagopalan S.V., Herrera B.M., Dyment D.A., Lincoln M.R., Montpetit A., et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:20896-20901.
4. Dyment D.A., Herrera B.M., Cader M.Z., Willer C.J., Lincoln M.R., Sadovnick A.D., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Human Molecular Genetics 2005, 14:2019-2026.
5. Oksenberg J.R., Barcellos L.F., Cree B.A., Baranzini S.E., Bugawan T.L., Khan O., et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. American Journal of Human Genetics 2004, 74:160-167.
6. Olerup O., Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991, 38:1-15.
7. Ramagopalan S.V., Deluca G.C., Morrison K.M., Herrera B.M., Dyment D.A., Lincoln M.R., et al. Analysis of 45 candidate genes for disease modifying activity in multiple sclerosis. Journal of Neurology 2008, 255:1215-1219.
8. Ramagopalan S.V., Morris A.P., Dyment D.A., Herrera B.M., DeLuca G.C., Lincoln M.R., et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genetics 2007, 3:1607-1613.
9. McDonald W.I. Multiple sclerosis: epidemiology and HLA associations. Annals of the New York Academy of Sciences 1984, 436:109-117.
10. Oksenberg J.R., Begovich A.B., Erlich H.A., Steinman L. Genetic factors in multiple sclerosis. Jama 1993, 270:2362-2369.
11. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Human Molecular Genetics 2006, 15:2813-2824.
12. Dyment D.A., Sadovnick A.D., Ebers G.C. Genetics of multiple sclerosis. Human Molecular Genetics 1997, 6:1693-1698.
13. Cullen C.G., Middleton D., Savage D.A., Hawkins S. HLA-DR and DQ DNA genotyping in multiple sclerosis patients in Northern Ireland. Human Immunology 1991, 30:1-6.
14. Marrosu M.G., Murru M.R., Costa G., Cucca F., Sotgiu S., Rosati G., et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. American Journal of Human Genetics 1997, 61:454-457.
15. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Annals of Neurology 2000, 48:211-219.
16. Weinshenker B.G., Santrach P., Bissonet A.S., McDonnell S.K., Schaid D., Moore S.B., et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998, 51:742-747.
17. Marrosu M.G., Muntoni F., Murru M.R., Spinicci G., Pischedda M.P., Goddi F., et al. Sardinian multiple sclerosis is associated with HLA-DR4: a serologic and molecular analysis. Neurology 1988, 38:1749-1753.
18. Zivadinov R., Uxa L., Bratina A., Bosco A., Srinivasaraghavan B., Minagar A., et al. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. International Review of Neurobiology 2007, 79:521-535.
19. Chao M.J., Barnardo M.C., Lincoln M.R., Ramagopalan S.V., Herrera B.M., Dyment D.A., et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:13069-13074.
20. Gold R., Hartung H.P., Toyka K.V. Animal models for autoimmune demyelinating disorders of the nervous system. Molecular Medicine Today 2000, 6:88-91.
21. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annual Review of Immunology 1992, 10:153-187.
22. Swanborg R.H. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunological Reviews 2001, 184:129-135.
23. Ando D.G., Clayton J., Kono D., Urban J.L., Sercarz E.E. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunology 1989, 124:132-143.
24. Kuchroo V.K., Anderson A.C., Waldner H., Munder M., Bettelli E., Nicholson L.B. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annual Review of Immunology 2002, 20:101-123.
25. Zamvil S.S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annual Review of Immunology 1990, 8:579-621.
26. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annual Review of Immunology 2009, 27:485-517.
27. Mangalam A.K., Rajagopalan G., Taneja V., David C.S. HLA class II transgenic mice mimic human inflammatory diseases. Advances in Immunology 2008, 97:65-147.
28. Greer J.M., Csurhes P.A., Cameron K.D., McCombe P.A., Good M.F., Pender M.P. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 1997, 120(Pt 8):1447-1460.
29. Martino G., Hartung H.P. Immunopathogenesis of multiple sclerosis: the role of T cells. Current Opinion in Neurology 1999, 12:309-321.
30. Schmidt S. Candidate autoantigens in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 1999, 5:147-160.
31. Mangalam A.K., Khare M., Krco C., Rodriguez M., David C. Identification of T cell epitopes on human proteolipid protein and induction of experimental autoimmune encephalomyelitis in HLA class II-transgenic mice. European Journal of Immunology 2004, 34:280-290.
32. Minohara M., Ochi H., Matsushita S., Irie A., Nishimura Y., Kira J. Differences between T-cell reactivities to major myelin protein-derived peptides in opticospinal and conventional forms of multiple sclerosis and healthy controls. Tissue Antigens 2001, 57:447-456.
33. Kawamura K., Yamamura T., Yokoyama K., Chui D.H., Fukui Y., Sasazuki T., et al. HLA-DR2-restricted responses to proteolipid protein 95-116 peptide cause autoimmune encephalitis in transgenic mice. The Journal of Clinical Investigation 2000, 105:977-984.
34. Mangalam A.K., Khare M., Krco C.J., Rodriguez M., David C.S. Delineation of the minimal encephalitogenic epitope of proteolipid protein peptide(91-110) and critical residues required for induction of EAE in HLA-DR3 transgenic mice. Journal of Neuroimmunology 2005, 161:40-48.
35. Ito K., Bian H.J., Molina M., Han J., Magram J., Saar E., et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. The Journal of Experimental Medicine 1996, 183:2635-2644.
36. Elliott E.A., McFarland H.I., Nye S.H., Cofiell R., Wilson T.M., Wilkins J.A., et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. The Journal of Clinical Investigation 1996, 98:1602-1612.
37. Amirzargar A., Mytilineos J., Yousefipour A., Farjadian S., Scherer S., Opelz G., et al. HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. European Journal of Immunogenetics 1998, 25:297-301.
38. Herrera B.M., Ebers G.C. Progress in deciphering the genetics of multiple sclerosis. Current Opinion in Neurology 2003, 16:253-258.
39. Das P., Drescher K.M., Geluk A., Bradley D.S., Rodriguez M., David C.S. Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis. Human Immunology 2000, 61:279-289.
40. Serjeantson S.W., Gao X., Hawkins B.R., Higgins D.A., Yu Y.L. Novel HLA-DR2-related haplotypes in Hong Kong Chinese implicate the DQB*0602 allele in susceptibility to multiple sclerosis. European Journal of Immunogenetics 1992, 19:11-19.
41. Marrosu M.G., Muntoni F., Murru M.R., Costa G., Pischedda M.P., Pirastu M., et al. HLA-DQB1 genotype in Sardinian multiple sclerosis: evidence for a key role of DQB1 *0201 and *0302 alleles. Neurology 1992, 42:883-886.
42. Mangalam A., Luckey D., Basal E., Behrens M., Rodriguez M., David C. HLA-DQ6 (DQB1*0601)-restricted T cells protect against experimental autoimmune encephalomyelitis in HLA-DR3.DQ6 double-transgenic mice by generating anti-inflammatory IFN-gamma. Journal of Immunology 2008, 180:7747-7756.
43. Steinman L. A rush to judgment on Th17. The Journal of Experimental Medicine 2008, 205:1517-1522.
44. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nature Medicine 2008, 14:337-342.
45. Khare M., Mangalam A., Rodriguez M., David C.S. HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice. Journal of Neuroimmunology 2005, 169:1-12.
46. Mangalam A., Luckey D., Basal E., Jackson M., Smart M., Rodriguez M., et al. HLA-DQ8 (DQB1*0302)-restricted Th17 cells exacerbate experimental autoimmune encephalomyelitis in HLA-DR3-transgenic mice. Journal of Immunology 2009, 182:5131-5139.
47. Hsu H.C., Yang P., Wang J., Wu Q., Myers R., Chen J., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nature Immunology 2008, 9:166-175.
48. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. Journal of Immunology 2006, 177:566-573.
49. Piddlesden S.J., Lassmann H., Zimprich F., Morgan B.P., Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. The American Journal of Pathology 1993, 143:555-564.
50. Raine C.S., Cannella B., Hauser S.L., Genain C.P. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Annals of Neurology 1999, 46:144-160.
51. Schluesener H.J., Sobel R.A., Linington C., Weiner H.L. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. Journal of Immunology 1987, 139:4016-4021.
52. Urich E., Gutcher I., Prinz M., Becher B. Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:18697-18702.
53. Pollinger B., Krishnamoorthy G., Berer K., Lassmann H., Bosl M.R., Dunn R., et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. The Journal of Experimental Medicine 2009, 206:1303-1316.
54. Du C., Sriram S. Increased severity of experimental allergic encephalomyelitis in lyn-/- mice in the absence of elevated proinflammatory cytokine response in the central nervous system. Journal of Immunology 2002, 168:3105-3112.
55. Rus H., Cudrici C., Niculescu F., Shin M.L. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. Journal of Neuroimmunology 2006, 180:9-16.
56. Cross A.H., Stark J.L. Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunologic Research 2005, 32:85-97.
57. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Medicine 1999, 5:170-175.
58. Linington C., Engelhardt B., Kapocs G., Lassman H. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. Journal of Neuroimmunology 1992, 40:219-224.
59. Martin Mdel P., Monson N.L. Potential role of humoral immunity in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Frontiers in Bioscience 2007, 12:2735-2749.
60. Szalai A.J., Hu X., Adams J.E., Barnum S.R. Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Molecular Immunology 2007, 44:3132-3136.
61. Youinou P. Haralampos M. Moutsopoulos: a lifetime in autoimmunity. Journal of Autoimmunity 2010, 35:171-175.
62. Miyagawa F., Gutermuth J., Zhang H., Katz S.I. The use of mouse models to better understand mechanisms of autoimmunity and tolerance. Journal of Autoimmunity 2010, 35:192-198.
63. Scheinecker C., Bonelli M., Smolen J.S. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. Journal of Autoimmunity 2010, 35:269-275.
64. Youinou P., Pers J.-O. The international symposium on Sjogren's syndrome in Brest: the "top of the tops" at the "tip of the tips". Autoimmunity Reviews 2010, 9:589-590.
65. Lu Q., Renaudineau Y., Cha S., Ilei G., Brooks W.H., Selmi C., et al. Epigenetics in autoimmune disorders: highlights of the 10th Sjogren's syndrome symposium. Autoimmunity Reviews 2010, 9:627-630.
66. Youinou P., Pers J.-O., Gershwin M.E., Shoenfeld Y. Geo-epidemiology and autoimmunity. Journal of Autoimmunity 2010, 34:J163-J167.
67. Chang C., Gershwin M.E. Drugs and autoimmunity - A contemporary review and mechanistic approach. Journal of Autoimmunity 2010, 34:J266-J275.
68. Borchers A.T., Naguwa S.M., Keen C.L., Gershwin M.E. The implications of autoimmunity and pregnancy. Journal of Autoimmunity 2010, 34:J287-J299.
69. Schilder A.M. Wegener's granulomatosis vasculitis and granuloma. Autoimmunity Reviews 2010, 9:483-487.
70. Ansari A.A., Gershwin M.E. Navigating the passage between Charybdis and Scylla: recognizing the achievements of Noel Rose. Journal of Autoimmunity 2009, 33:165-169.
71. Mackay I.R. Clustering and commonalities among autoimmune diseases. Journal of Autoimmunity 2009, 33:170-177.